Citations

Clear

6274 citation(s) found for "To, Andrew".

Primary intra‐abdominal melanoma arising in association with extracutaneous blue naevus: a report of two cases
Shah, Kabeer , Folpe, Andrew L. , Morgan, Jeffrey A. , Raut, Chandrajit P. , Doyle, Leona A. , Doyle, Leona A , Miller, Michael J.

Mayo Clinic

Histopathology | July 22, 2020 | Volume: 78 | Issue: 2 | Pages: 281-289

10.1111/his.14219 | PMID 32698251 Get It

AimsBlue naevi are uncommon dermal melanocytic neoplasms characterised by GNAQ/GNA11 mutations, which very rarely progress to melanoma. Such melanomas also often have BAP1 mutations, and lack genetic events associated with conventional melanoma. Exceptionally, blue naevi arise in extracutaneous locations; one melanoma arising in this setting has been reported. We report the clinicopathological, immunohistochemical and molecular genetic features of two cases of melanoma arising in extracutaneous blue naevus.Methods and resultsBoth arose in males, aged 25 and 63 years, with no history of other melanocytic lesions, and presented as large, painful intra‐abdominal masses. The tumours were dark‐brown/black, multilobulated, involved small intestinal mesentery and consisted of a predominantly fascicular and spindled, but occasionally nested and epithelioid, proliferation of variably pigmented, relatively monotonous cells with pale cytoplasm and ovoid nuclei with mild to moderate atypia. Mitotic activity was variable but generally low. Both cases showed areas of conventional and cellular blue naevus. Recurrent tumour in one case showed predominantly epithelioid morphology and greater cytological atypia and mitotic activity. One case expressed Melan‐A, SOX10 and CD117, with absent expression of S100 protein and DOG1; the other expressed Melan‐A, HMB45 and S100 protein. Next‐generation sequencing identified GNAQ and BAP1 mutations in one case and GNA11 mutation in the other. Both patients developed widespread metastatic disease.ConclusionExceptionally rare, aggressive melanomas arising in extracutaneous blue naevi should be distinguished from metastatic melanoma, gastrointestinal stromal tumour and malignant melanotic nerve sheath tumour, especially given the significant therapeutic and prognostic differences between these different entities.
Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study
Rivera, Donna R. , Peters, Solange , Shah, Dimpy P. , Kuderer, Nicole M. , Hsu, Chih–Yuan , Rubinstein, Samuel M. , Lee, Brendan J., Choueiri, Toni K. , Lopes, Gilberto , Grivas, Petros , Arcobello, Jonathan , Bakouny, Ziad , Doroshow, Deborah B. , Egan, Pamela , Fecher, Leslie A. , Friese, Christopher R. , Galsky, Matthew D. , Gupta, Shilpa , Hálfdánarson, Þorvarður R. , Halmos, Balázs , Khaki, Ali Raza , Lemmon, Christopher A. , Mishra, Sanjay , Puc, Matthew , Revankar, Sanjay G. , Schapira, Lidia , Schmidt, Andrew , Shah, Sumit , Wu, Julie , Xie, Zhuoer , Yeh, Albert C. , Zhu, Huili , Shyr, Yu , Grivas, Petros , Bakouny, Ziad , Galsky, Matthew D , Goel, Sanjay , Halfdanarson, Thorvardur R , Hawley, Jessica E , Mishra, Sanjay , Pennell, Nathan A , Puc, Matthew M , Revankar, Sanjay G , Wu, Julie T , Yeh, Albert C , Warner, Jeremy L , Peters, Solange , Choueiri, Toni K , Xie, Zhuoer , Khaki, Ali Raza , Panagiotou, Orestis A. , Painter, Corrie , Rini, Brian I. , Thompson, Michael A. , Farmakiotis, Dimitrios , Goel, Sanjay , Hawley, Jessica E. , Olszewski, Adam J. , Schwartz, Gary K. , Lyman, Gary H , Warner, Jeremy L. , Halmos, Balazs

Mayo Clinic

Cancer Discovery | July 22, 2020 | Volume: 10 | Issue: 10 | Pages: 1514-1527

10.1158/2159-8290.cd-20-0941 | PMID 32699031 Get It

Abstract Among 2,186 U.S. adults with invasive cancer and laboratory-confirmed SARS-CoV-2 infection, we examined the association of COVID-19 treatments with 30-day all-cause mortality and factors associated with treatment. Logistic regression with multiple adjustments (e.g., comorbidities, cancer status, baseline COVID-19 severity) was performed. Hydroxychloroquine with any other drug was associated with increased mortality versus treatment with any COVID-19 treatment other than hydroxychloroquine or untreated controls; this association was not present with hydroxychloroquine alone. Remdesivir had numerically reduced mortality versus untreated controls that did not reach statistical significance. Baseline COVID-19 severity was strongly associated with receipt of any treatment. Black patients were approximately half as likely to receive remdesivir as white patients. Although observational studies can be limited by potential unmeasured confounding, our findings add to the emerging understanding of patterns of care for patients with cancer and COVID-19 and support evaluation of emerging treatments through inclusive prospective controlled trials. Significance: Evaluating the potential role of COVID-19 treatments in patients with cancer in a large observational study, there was no statistically significant 30-day all-cause mortality benefit with hydroxychloroquine or high-dose corticosteroids alone or in combination; remdesivir showed potential benefit. Treatment receipt reflects clinical decision-making and suggests disparities in medication access. This article is highlighted in the In This Issue feature, p. 1426
An International Multicenter Evaluation of Inheritance Patterns, Arrhythmic Risks, and Underlying Mechanisms of CASQ2 -Catecholaminergic Polymorphic Ventricular Tachycardia
Ng, Kevin, Titus, Erron W. , Lieve, Krystien V.V. , Roston, Thomas M. , Mazzanti, Andrea , Deiter, Fred , Ingles, Jodie , Till, Jan , Robyns, Tomas , Connors, Sean P., Pang, B. , Bos, J. Martijn , Duffett, Stephen A. , Maltret, Alice , Green, Martin S. , Rutberg, Julie, Balaji, Seshadri , Cadrin‐Tourigny, Julia , Orland, Kate M. , Knight, Linda M., Brateng, Caitlin, Wu, Jeremy , Tang, Anthony , Skanes, Allan C. , Manlucu, Jaimie , January, Craig T., Collins, Kathryn K. , Maginot, Kathleen R., Fischbach, Peter , Etheridge, Susan P. , Eckhardt, Lee L. , Hamilton, Robert M. , Ackerman, Michael J. , Rosés‐Noguer, Ferran , Semsarian, Christopher , Jura, Natalia , Priori, Silvia G. , Sanatani, Shubhayan , Wilde, Arthur A.M. , Deo, Rahul C. , Roberts, Jason D. , Eckhardt, Lee L , Bos, Johan M , Robyns, Tomas , Sanatani, Shubhayan , Hamilton, Robert , Rosés-Noguer, Ferran , Mazzanti, Andrea , Cadrin-Tourigny, Julia , Ingles, Jodie , Priori, Silvia , Lieve, Krystien V , Denjoy, Isabelle , Connors, Sean P., Steinberg, Christian , Abrams, Dominic J. , Scheinman, Melvin M , Werf, Christian van der , Knight, Linda M., Healey, Jeff S. , Krahn, Andrew D. , Leenhardt, Antoine , Gollob, Michael H.

Mayo Clinic

Circulation | July 22, 2020 | Volume: 142 | Issue: 10 | Pages: 932-947

10.1161/circulationaha.120.045723 | PMID 32693635 Get It

Background: Genetic variants in calsequestrin-2 ( CASQ2 ) cause an autosomal recessive form of catecholaminergic polymorphic ventricular tachycardia (CPVT), although isolated reports have identified arrhythmic phenotypes among heterozygotes. Improved insight into the inheritance patterns, arrhythmic risks, and molecular mechanisms of CASQ2 -CPVT was sought through an international multicenter collaboration. Methods: Genotype-phenotype segregation in CASQ2 -CPVT families was assessed, and the impact of genotype on arrhythmic risk was evaluated using Cox regression models. Putative dominant CASQ2 missense variants and the established recessive CASQ2-p.R33Q variant were evaluated using oligomerization assays and their locations mapped to a recent CASQ2 filament structure. Results: A total of 112 individuals, including 36 CPVT probands (24 homozygotes/compound heterozygotes and 12 heterozygotes) and 76 family members possessing at least 1 presumed pathogenic CASQ2 variant, were identified. Among CASQ2 homozygotes and compound heterozygotes, clinical penetrance was 97.1% and 26 of 34 (76.5%) individuals had experienced a potentially fatal arrhythmic event with a median age of onset of 7 years (95% CI, 6–11). Fifty-one of 66 CASQ2 heterozygous family members had undergone clinical evaluation, and 17 of 51 (33.3%) met diagnostic criteria for CPVT. Relative to CASQ2 heterozygotes, CASQ2 homozygote/compound heterozygote genotype status in probands was associated with a 3.2-fold (95% CI, 1.3–8.0; P =0.013) increased hazard of a composite of cardiac syncope, aborted cardiac arrest, and sudden cardiac death, but a 38.8-fold (95% CI, 5.6–269.1; P <0.001) increased hazard in genotype-positive family members. In vitro turbidity assays revealed that p.R33Q and all 6 candidate dominant CASQ2 missense variants evaluated exhibited filamentation defects, but only p.R33Q convincingly failed to dimerize. Structural analysis revealed that 3 of these 6 putative dominant negative missense variants localized to an electronegative pocket considered critical for back-to-back binding of dimers. Conclusions: This international multicenter study of CASQ2 -CPVT redefines its heritability and confirms that pathogenic heterozygous CASQ2 variants may manifest with a CPVT phenotype, indicating a need to clinically screen these individuals. A dominant mode of inheritance appears intrinsic to certain missense variants because of their location and function within the CASQ2 filament structure.
Vascular dysfunction in aged mice contributes to persistent lung fibrosis
Caporarello, Nunzia , Meridew, Jeffrey A., Aravamudhan, Aja, Jones, Dakota L. , Austin, Susan A., Pham, Tho X., Haak, Andrew J. , Choi, Kyoung Moo , Tan, Qi , Haresi, Adil J. , Huang, Steven K. , Katušić, Zvonimir S. , Tschumperlin, Daniel J. , Ligresti, Giovanni , Moo Choi, Kyoung, Caporarello, Nunzia

Mayo Clinic

Aging Cell | July 21, 2020 | Volume: 19 | Issue: 8 | Pages: No page available

10.1111/acel.13196 | PMID 32691484 Get It

Abstract Idiopathic pulmonary fibrosis (IPF) is a progressive disease thought to result from impaired lung repair following injury and is strongly associated with aging. While vascular alterations have been associated with IPF previously, the contribution of lung vasculature during injury resolution and fibrosis is not well understood. To compare the role of endothelial cells (ECs) in resolving and non‐resolving models of lung fibrosis, we applied bleomycin intratracheally to young and aged mice. We found that injury in aged mice elicited capillary rarefaction, while injury in young mice resulted in increased capillary density. ECs from the lungs of injured aged mice relative to young mice demonstrated elevated pro‐fibrotic and reduced vascular homeostasis gene expression. Among the latter, Nos3 (encoding the enzyme endothelial nitric oxide synthase, eNOS) was transiently upregulated in lung ECs from young but not aged mice following injury. Young mice deficient in eNOS recapitulated the non‐resolving lung fibrosis observed in aged animals following injury, suggesting that eNOS directly participates in lung fibrosis resolution. Activation of the NO receptor soluble guanylate cyclase in human lung fibroblasts reduced TGFβ‐induced pro‐fibrotic gene and protein expression. Additionally, loss of eNOS in human lung ECs reduced the suppression of TGFβ‐induced lung fibroblast activation in 2D and 3D co‐cultures. Altogether, our results demonstrate that persistent lung fibrosis in aged mice is accompanied by capillary rarefaction, loss of EC identity, and impaired eNOS expression. Targeting vascular function may thus be critical to promote lung repair and fibrosis resolution in aging and IPF.
Nine-year prospective efficacy and safety of brain-responsive neurostimulation for focal epilepsy
Nair, Dileep , Laxer, Kenneth D. , Weber, Peter, Murro, Anthony M., Park, Yong D., Barkley, Gregory L., Smith, Brien, Gwinn, Ryder P. , Doherty, Michael J. , Zimmerman, Richard S. , Bergey, Gregory K. , Anderson, William S. , Heck, Christianne, Liu, Charles Y. , Lee, Ricky W. , Sadler, Toni, Duckrow, Robert B., Wharen, Robert E. , Tatum, William O. , Srinivasan, Shraddha, Agostini, Mark, Alexopoulos, Andreas V. , Jobst, Barbara C. , Roberts, David W. , Salanova, Vicenta , Witt, Thomas C., Cash, Sydney S. , Halford, Jonathan J. , Spencer, David , Ernst, Lia , Skidmore, Christopher , Sperling, Michael R. , Miller, Ian , Geller, Eric B., Berg, Michel J., Fessler, A. James, Rutecki, Paul , Mizrahi, Eli M., Shields, Donald C. , Schwartz, Theodore H. , Labar, Douglas, Fountain, Nathan B. , Elias, W. Jeff, Olejniczak, Piotr W., Villemarette-Pittman, Nicole R. , Eisenschenk, Stephan, Roper, Steven N. , Boggs, Jane , Courtney, Tracy A., Sun, Felice T., Seale, Cairn G. , Miller, Kathy L. , Skarpaas, Tara L. , Morrell, Martha J. , Study, on behalf of the RNS System LTT, Meador, Kimford J. , Vossler, David G. , Hays, Ryan , Liow, Kore , Nair, Dileep R, Weber, Peter B, Smith, Brien J, Noe, Katherine H. , McKhann, Guy M. , Agostini, Mark A, Alexopoulos, Andreas V , Edwards, Jonathan C, Spencer, David C, Skidmore, Christopher T., Goldman, Alica M. , Gross, Robert E, Labar, Douglas R, Boggs, Jane G, Sperling, Michael R , Halford, Jonathan J , Fountain, Nathan , Meador, Kimford J , Jobst, Barbara , Nair, Dileep R , Skidmore, Christopher , Morrell, Martha J , Ernst, Lia D , Hirsch, Lawrence J. , Cole, Andrew J. , Worrell, Gregory A. , Lundstrom, Brian N. , Edwards, Jonathan C. W. , Gross, Robert E. , Study, on behalf of the RNS System LTT

Mayo Clinic

Neurology | July 20, 2020 | Volume: 95 | Issue: 9 | Pages: No page available

10.1212/wnl.0000000000010154 | PMID 32690786 Get It

International consensus guidelines for phosphoglucomutase 1 deficiency ( PGM1‐CDG ): Diagnosis, follow‐up, and management
Altassan, Ruqaiah , Radenkovic, Silvia , Edmondson, Andrew C. , Barone, Rita , Brasil, Sandra , Čechová, Anna , Coman, David , Donoghue, Sarah , Falkenstein, Kristina , Ferreira, Vanessa dos Reis , Fiumara, Agata , Francisco, Rita , Grünewald, Stephanie , Jaeken, Jaak , Krasnewich, Donna M., Lam, Christina , Lefeber, Dirk J. , Marques‐da‐Silva, Dorinda , Pascoal, Carlota , Quelhas, Dulce , Raymond, Kimiyo , Rymen, Daisy , Seroczyńska, Małgorzata, Serrano, Mercedes , Thiel, Christian , Tort, Frederic , Vals, Mari‐Anne , Videira, Paula A. , Raymond, Kimiyo M, Donoghue, Sarah E , Edmondson, Andrew C , Pascoal, Carlota , Videira, Paula A , Ferreira, Carlos R , Freeze, Hudson H. , Honzík, Tomáš , Lee, Joy Li-Yueh , Sykut‐Cegielska, Jolanta , Voermans, Nicol Cornelia , Witters, Peter , Morava, Éva

Mayo Clinic

Journal of Inherited Metabolic Disease | July 18, 2020 | Volume: 44 | Issue: 1 | Pages: 148-163

10.1002/jimd.12286 | PMID 32681750 Get It

Abstract Phosphoglucomutase 1 (PGM1) deficiency is a rare genetic disorder that affects glycogen metabolism, glycolysis, and protein glycosylation. Previously known as GSD XIV, it was recently reclassified as a congenital disorder of glycosylation, PGM1‐CDG. PGM1‐CDG usually manifests as a multisystem disease. Most patients present as infants with cleft palate, liver function abnormalities and hypoglycemia, but some patients present in adulthood with isolated muscle involvement. Some patients develop life‐threatening cardiomyopathy. Unlike most other CDG, PGM1‐CDG has an effective treatment option, d ‐galactose, which has been shown to improve many of the patients' symptoms. Therefore, early diagnosis and initiation of treatment for PGM1‐CDG patients are crucial decisions. In this article, our group of international experts suggests diagnostic, follow‐up, and management guidelines for PGM1‐CDG. These guidelines are based on the best available evidence‐based data and experts' opinions aiming to provide a practical resource for health care providers to facilitate successful diagnosis and optimal management of PGM1‐CDG patients.
Safety and efficacy of (+)‐epicatechin in subjects with Friedreich's ataxia: A phase II , open‐label, prospective study
Qureshi, M. Yasir , Clark, Vicki M., Johnson, Jonathan N. , Moutvic, Margaret A., Driscoll, Sherilyn W. , Kemppainen, Jennifer L., Badley, Andrew D. , Tebben, Peter J. , Wackel, Philip L. , Oglesbee, Devin , Glockner, James F., Schreiner, George F., Touchette, Jillienne C. , Gavrilova, Ralitza H. , Qureshi, Muhammad Yasir, Patterson, Marc C. , Clark, Vicki, Anderson, Jeff R , Glockner, James, Qureshi, Muhammad Y , Oglesbee, Devin , Badley, Andrew D , Tebben, Peter , Huston, John , Anderson, Jeff R., Dugar, Sundeep

Mayo Clinic

Journal of Inherited Metabolic Disease | July 17, 2020 | Volume: 44 | Issue: 2 | Pages: 502-514

10.1002/jimd.12285 | PMID 32677106 Get It

Abstract Background (+)‐Epicatechin (EPI) induces mitochondrial biogenesis and antioxidant metabolism in muscle fibers and neurons. We aimed to evaluate safety and efficacy of (+)‐EPI in pediatric subjects with Friedreich's ataxia (FRDA). Methods This was a phase II, open‐label, baseline‐controlled single‐center trial including 10 participants ages 10 to 22 with confirmed FA diagnosis. (+)‐EPI was administered orally at 75 mg/d for 24 weeks, with escalation to 150 mg/d at 12 weeks for subjects not showing improvement of neuromuscular, neurological or cardiac endpoints. Neurological endpoints were change from baseline in Friedreich's Ataxia Rating Scale (FARS) and 8‐m timed walk. Cardiac endpoints were changes from baseline in left ventricular (LV) structure and function by cardiac magnetic resonance imaging (MRI) and echocardiogram, changes in cardiac electrophysiology, and changes in biomarkers for heart failure and hypertrophy. Results Mean FARS/modified (m)FARS scores showed nonstatistically significant improvement by both group and individual analysis. FARS/mFARS scores improved in 5/9 subjects (56%), 8‐m walk in 3/9 (33%), 9‐peg hole test in 6/10 (60%). LV mass index by cardiac MRI was significantly reduced at 12 weeks ( P = .045), and was improved in 7/10 (70%) subjects at 24 weeks. Mean LV ejection fraction was increased at 24 weeks ( P = .008) compared to baseline. Mean maximal septal thickness by echocardiography was increased at 24 weeks ( P = .031). There were no serious adverse events. Conclusion (+)‐EPI was well tolerated over 24 weeks at up to 150 mg/d. Improvement was observed in cardiac structure and function in subset of subjects with FRDA without statistically significant improvement in primary neurological outcomes. Synopsis A (+)‐epicatechin showed improvement of cardiac function, nonsignificant reduction of FARS/mFARS scores, and sustained significant upregulation of muscle‐regeneration biomarker follistatin.
Active women demonstrate acute autonomic and hemodynamic shifts following exercise in heat and humidity: A pilot study
Zabriskie, Hannah A. , Kerksick, Chad M. , Jagim, Andrew R , Kerksick, Chad M , Zabriskie, Hannah A , Jagim, Andrew R.

Mayo Clinic

Temperature | July 17, 2020 | Volume: 8 | Issue: 1 | Pages: 64-79

10.1080/23328940.2020.1796242 | PMID 33553506 Get It

A Rare TP53 Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple Cancers
Powers, Jacquelyn , Pinto, Emília M. , Barnoud, Thibaut , Leung, Jessica C. , Martynyuk, Tetyana , Kossenkov, Andrew V. , Philips, Aaron H., Desai, Heena , Hausler, Ryan , Le, Anh N. , Pyle, Louise C. , Zelley, Kristin , Nathanson, Katherine L. , Slavin, Thomas P. , Weitzel, Jeffrey N. , Stopfer, Jill E. , Offit, Kenneth , Dolinsky, Jill S. , Gutierrez, Stephanie, McGoldrick, Kelly , Levin, Brooke , Edelman, Morris, Levy, Carolyn Fein , Spunt, Sheri L. , Zambetti, Gerard P. , Li, Marilyn M , MacFarland, Suzanne P , Pyle, Louise C , Zelley, Kristin , Domchek, Susan M , Weitzel, Jeffrey N , Garber, J. E. , Joseph, Vijai , Levin, Brooke , Levy, Carolyn Fein , Spunt, Sheri L , Nathanson, Katherine L , Kelly, Gregory, Domchek, Susan M. , Garber, Judy E. , Vijai, Joseph , Couch, Fergus J. , Kriwacki, Richard W. , Ribeiro, Raul C , Murphy, Maureen E. , Maxwell, Kara N.

Mayo Clinic

Cancer Research | July 16, 2020 | Volume: 80 | Issue: 17 | Pages: 3732-3744

10.1158/0008-5472.can-20-1390 | PMID 32675277 Get It

Abstract Germline mutations in TP53 cause a rare high penetrance cancer syndrome, Li–Fraumeni syndrome (LFS). Here, we identified a rare TP53 tetramerization domain missense mutation, c.1000G&gt;C;p.G334R, in a family with multiple late-onset LFS-spectrum cancers. Twenty additional c.1000G&gt;C probands and one c.1000G&gt;A proband were identified, and available tumors showed biallelic somatic inactivation of TP53. The majority of families were of Ashkenazi Jewish descent, and the TP53 c.1000G&gt;C allele was found on a commonly inherited chromosome 17p13.1 haplotype. Transient transfection of the p.G334R allele conferred a mild defect in colony suppression assays. Lymphoblastoid cell lines from the index family in comparison with TP53 normal lines showed that although classical p53 target gene activation was maintained, a subset of p53 target genes (including PCLO, PLTP, PLXNB3, and LCN15) showed defective transactivation when treated with Nutlin-3a. Structural analysis demonstrated thermal instability of the G334R-mutant tetramer, and the G334R-mutant protein showed increased preponderance of mutant conformation. Clinical case review in comparison with classic LFS cohorts demonstrated similar rates of pediatric adrenocortical tumors and other LFS component cancers, but the latter at significantly later ages of onset. Our data show that TP53 c.1000G&gt;C;p.G334R is found predominantly in Ashkenazi Jewish individuals, causes a mild defect in p53 function, and leads to low penetrance LFS. Significance: TP53 c.1000C&gt;G;p.G334R is a pathogenic, Ashkenazi Jewish–predominant mutation associated with a familial multiple cancer syndrome in which carriers should undergo screening and preventive measures to reduce cancer risk.